November 16, 2016 05:57 AM ESTUpdated 10:03 AM

Bristol-Myers partners with Enterome on a gut-level approach to immuno-oncology; MorphoSys adds $126M

Shehla Shakoor

Managing Director

Bristol-Myers Squibb has turned to Paris-based microbiome expert Enterome for its latest immuno-oncology partnership. The biotech landed a $15 million upfront and unspecified, research …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol-Myers partners with Enterome on a gut-level approach to immuno-oncology; MorphoSys adds $126M

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lexicon ends commercial work to focus on R&D

Are programs with compounded GLP-1s safe for your population?

Bris­tol-My­ers part­ners with En­terome on a gut-lev­el ap­proach to im­muno-on­col­o­gy; Mor­phoSys adds $126M

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lex­i­con ends com­mer­cial work to fo­cus on R&D

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Bristol-Myers partners with Enterome on a gut-level approach to immuno-oncology; MorphoSys adds $126M

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lexicon ends commercial work to focus on R&D

Are programs with compounded GLP-1s safe for your population?